Mice heterozygous for a defect in mitochondrial trifunctional protein develop hepatic steatosis and insulin resistance
about
Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primatesThe blind men 'see' the elephant-the many faces of fatty liver diseaseGenetically modified mouse models for the study of nonalcoholic fatty liver diseaseRole of mitochondria in nonalcoholic fatty liver diseaseTransient elastography (FibroScan(®)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?Sirtuins and nonalcoholic fatty liver diseaseMitochondrial dysfunction in fatty acid oxidation disorders: insights from human and animal studiesALCAT1 controls mitochondrial etiology of fatty liver diseases, linking defective mitophagy to steatosisMitochondrial Trifunctional Protein Defects: Clinical Implications and Therapeutic ApproachesEriocitrin ameliorates diet-induced hepatic steatosis with activation of mitochondrial biogenesis.Functional proteomic analysis of nonalcoholic fatty liver disease in rat models: enoyl-coenzyme a hydratase down-regulation exacerbates hepatic steatosis.Skeletal muscle mitochondrial and metabolic responses to a high-fat diet in female rats bred for high and low aerobic capacity.Mitochondrial dysfunction precedes insulin resistance and hepatic steatosis and contributes to the natural history of non-alcoholic fatty liver disease in an obese rodent model.Cardiolipin remodeling by ALCAT1 links oxidative stress and mitochondrial dysfunction to obesity.Differing endoplasmic reticulum stress response to excess lipogenesis versus lipid oversupply in relation to hepatic steatosis and insulin resistance.Expression of miR-33 from an SREBP2 intron inhibits cholesterol export and fatty acid oxidation.Targeting Forkhead box O1 from the concept to metabolic diseases: lessons from mouse models.Daily exercise vs. caloric restriction for prevention of nonalcoholic fatty liver disease in the OLETF rat model.Keap1-knockdown decreases fasting-induced fatty liver via altered lipid metabolism and decreased fatty acid mobilization from adipose tissueMitochondrial aldehyde dehydrogenase activation by Alda-1 inhibits atherosclerosis and attenuates hepatic steatosis in apolipoprotein E-knockout mice.Hepatitis C virus attenuates mitochondrial lipid β-oxidation by downregulating mitochondrial trifunctional-protein expression.Hepatic Steatosis as a Marker of Metabolic Dysfunction.The non-invasive (13)C-methionine breath test detects hepatic mitochondrial dysfunction as a marker of disease activity in non-alcoholic steatohepatitisStrategies, models and biomarkers in experimental non-alcoholic fatty liver disease researchDetection of Placental Proteomes at Different Uterine Positions in Large White and Meishan Gilts on Gestational Day 90.Proteomics Analysis to Identify and Characterize the Molecular Signatures of Hepatic Steatosis in Ovariectomized Rats as a Model of Postmenopausal StatusPGC-1α overexpression results in increased hepatic fatty acid oxidation with reduced triacylglycerol accumulation and secretion.Mouse models in non-alcoholic fatty liver disease and steatohepatitis research.Metformin Restores Parkin-Mediated Mitophagy, Suppressed by Cytosolic p53.Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implicationsThe presence of the ovary prevents hepatic mitochondrial oxidative stress in young and aged female mice through glutathione peroxidase 1Pathogenesis and Prevention of Hepatic Steatosis.Pleiotropic effects of rosuvastatin on the glucose metabolism and the subcutaneous and visceral adipose tissue behavior in C57Bl/6 miceNonalcoholic fatty liver disease and mitochondrial dysfunction.Molecular mechanisms of alcoholic fatty liverCessation of daily wheel running differentially alters fat oxidation capacity in liver, muscle, and adipose tissueOxidative stress-mediated mitochondrial dysfunction contributes to angiotensin II-induced nonalcoholic fatty liver disease in transgenic Ren2 ratsAcute fatty liver of pregnancy: an update on mechanismsNutritional management of insulin resistance in nonalcoholic fatty liver disease (NAFLD).Acetylation of Mitochondrial Trifunctional Protein α-Subunit Enhances Its Stability To Promote Fatty Acid Oxidation and Is Decreased in Nonalcoholic Fatty Liver Disease.
P2860
Q24646644-3363FA38-5382-4C35-B47C-C78EE3BBE81EQ24654991-21A1999F-762C-4FF2-8F21-AC0773230BE0Q26865248-1AE9E344-5E94-48B9-8747-BAAC73C64D25Q27028142-03EC3EC9-1443-4FE4-B648-4E77FE8E6DF2Q28079445-52D5CAA4-1EBC-4019-9B6F-CFD8F990ABC6Q28079953-FA14BCF9-C0B9-4569-ACE9-34B1ED619310Q28085600-13DC880E-5C87-48CF-BF0A-9DCF4CFDE554Q28386269-FC26AC7D-8FC1-431B-BAD1-927EE129F3F6Q28972544-B583879D-A6BE-4119-9885-631C1C70933AQ30564438-7713CCA2-E092-4FB6-8FBA-4E378D44E204Q33531866-E4B26B3D-02BA-422F-94A4-4EF479EBA7ACQ33950633-E1E28EE5-E7FE-4F26-A5A8-5BB77A234DAFQ34021867-BCF7CB29-8A0F-4B11-9997-6BBC3D6E94C1Q34072371-253BBAE0-DE1B-4025-911D-C3D639F57478Q34166238-7D33C033-D30A-40AF-B763-B3F086095E5DQ34231924-B422644C-EC70-4F69-9424-B9936955C7E6Q34514818-F783F6D6-5F8F-4F9B-8247-CB0EF018AF04Q34979962-54BBDF7B-BD1A-4A98-90C0-0B23C7A6B8CCQ35041508-27311E5B-C6CC-447B-99BC-555F45824522Q35115065-7B26D36E-DC19-4B8B-820B-B849C89FCBBAQ35641048-D3002236-A21E-4ADC-9FEC-D4D4234070A2Q35809069-8ACEF075-3CDC-4CB2-A537-93D8D7025DA2Q35963873-B30E0D2D-DF78-40FA-A16D-5F2D97C30352Q36129673-23D97D84-3CE2-48B6-A719-6CF917DA0DDCQ36218125-A5E134A0-6D13-49E1-897A-BD7EAA5E14BCQ36246843-59AD8A98-CD3A-402D-9AF3-88B182C193D5Q36312713-969D89A8-5957-4C49-88B9-1904D30FA1EEQ36377266-1DBEDE84-C2C0-46E5-A214-D6BA2E4B2107Q36512678-7C276FEA-B8A4-4175-A732-194B81042C9CQ36617551-E3D28CE2-4037-467A-ADAE-6A65743CA9E3Q36776359-A494C198-0FAF-4042-9910-5C01369E33E9Q36812508-D4028D86-EB50-430B-BEC6-F10DB793FA01Q37028323-6E9BFA8B-E5E1-4DB0-8D42-553FCB6CF889Q37054354-D1CBD3C9-96E3-4407-9C41-430EDED2FD21Q37078754-B2AF16FB-F05D-421C-994C-22676595BC9FQ37086221-16182217-32C7-435C-A63A-17DC579937A5Q37164536-6A1ED56B-2078-4C1F-9073-7A82F7B69F16Q37185906-C39E364E-DA6B-4E11-90A0-5D907E8B9976Q37286751-DFE1608B-1C97-4F9C-90EB-3C748051B832Q37287396-9416259D-B763-4458-8E83-E7B230B7DCE3
P2860
Mice heterozygous for a defect in mitochondrial trifunctional protein develop hepatic steatosis and insulin resistance
description
2005 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մայիսին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2005
@ast
im Mai 2005 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2005/05/01)
@sk
vědecký článek publikovaný v roce 2005
@cs
wetenschappelijk artikel (gepubliceerd op 2005/05/01)
@nl
наукова стаття, опублікована в травні 2005
@uk
مقالة علمية (نشرت في مايو 2005)
@ar
name
Mice heterozygous for a defect ...... eatosis and insulin resistance
@ast
Mice heterozygous for a defect ...... eatosis and insulin resistance
@en
Mice heterozygous for a defect ...... eatosis and insulin resistance
@nl
type
label
Mice heterozygous for a defect ...... eatosis and insulin resistance
@ast
Mice heterozygous for a defect ...... eatosis and insulin resistance
@en
Mice heterozygous for a defect ...... eatosis and insulin resistance
@nl
prefLabel
Mice heterozygous for a defect ...... eatosis and insulin resistance
@ast
Mice heterozygous for a defect ...... eatosis and insulin resistance
@en
Mice heterozygous for a defect ...... eatosis and insulin resistance
@nl
P2093
P921
P1433
P1476
Mice heterozygous for a defect ...... eatosis and insulin resistance
@en
P2093
Dietrich Matern
Hermina Borgerink
J. Mark Cline
Jamal A. Ibdah
Janice D. Wagner
Jerry Angdisen
Melanie K. Shadoan
Peter Perlegas
Piero Rinaldo
Yiwen Zhao
P304
P356
10.1053/J.GASTRO.2005.02.001
P407
P577
2005-05-01T00:00:00Z